Last reviewed · How we verify
Budesonide 200 µg
At a glance
| Generic name | Budesonide 200 µg |
|---|---|
| Also known as | Budesonide 200 µg (test product (B)) |
| Sponsor | Reig Jofre Group |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler (NA)
- A Comparative Study Between Foraseq and Formoterol/Budesonide Inhalation Capsules in Patients with Asthma (PHASE3)
- Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (PHASE4)
- Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD (PHASE3)
- Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (PHASE3)
- Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma (PHASE3)
- A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR) (PHASE3)
- Inhaled Budesonide and Acute Mountain Sickness (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide 200 µg CI brief — competitive landscape report
- Budesonide 200 µg updates RSS · CI watch RSS
- Reig Jofre Group portfolio CI